148 related articles for article (PubMed ID: 26972877)
1. E84G mutation in dihydrofolate reductase from drug resistant strains of Mycobacterium tuberculosis (Mumbai, India) leads to increased interaction with Trimethoprim.
Raju A; Kulkarni S; Ray MK; Rajan MG; Degani MS
Int J Mycobacteriol; 2015 Jun; 4(2):97-103. PubMed ID: 26972877
[TBL] [Abstract][Full Text] [Related]
2. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
Cheng YS; Sacchettini JC
Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
[TBL] [Abstract][Full Text] [Related]
3. Increased substrate affinity in the Escherichia coli L28R dihydrofolate reductase mutant causes trimethoprim resistance.
Abdizadeh H; Tamer YT; Acar O; Toprak E; Atilgan AR; Atilgan C
Phys Chem Chem Phys; 2017 May; 19(18):11416-11428. PubMed ID: 28422217
[TBL] [Abstract][Full Text] [Related]
4. Mycobacterium tuberculosis dihydrofolate reductase reveals two conformational states and a possible low affinity mechanism to antifolate drugs.
Dias MV; Tyrakis P; Domingues RR; Paes Leme AF; Blundell TL
Structure; 2014 Jan; 22(1):94-103. PubMed ID: 24210757
[TBL] [Abstract][Full Text] [Related]
5. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
[TBL] [Abstract][Full Text] [Related]
6. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.
Wang F; Jain P; Gulten G; Liu Z; Feng Y; Ganesula K; Motiwala AS; Ioerger TR; Alland D; Vilchèze C; Jacobs WR; Sacchettini JC
Antimicrob Agents Chemother; 2010 Sep; 54(9):3776-82. PubMed ID: 20566771
[TBL] [Abstract][Full Text] [Related]
7. Cloning, expression, and characterization of Mycobacterium tuberculosis dihydrofolate reductase.
White EL; Ross LJ; Cunningham A; Escuyer V
FEMS Microbiol Lett; 2004 Mar; 232(1):101-5. PubMed ID: 15019741
[TBL] [Abstract][Full Text] [Related]
8. Phylogenetic and Structural Significance of Dihydrofolate Synthase (folC) Mutations in Drug-Resistant Mycobacterium tuberculosis.
Cheng VW; Leung KS; Kwok JS; Leung RK; Yang KY; Chan RC; Kam KM; Tsui SK
Microb Drug Resist; 2016 Oct; 22(7):545-551. PubMed ID: 27082669
[TBL] [Abstract][Full Text] [Related]
9. Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques.
Vickers AA; Potter NJ; Fishwick CW; Chopra I; O'Neill AJ
J Antimicrob Chemother; 2009 Jun; 63(6):1112-7. PubMed ID: 19383727
[TBL] [Abstract][Full Text] [Related]
10. Role of embCAB gene mutations in ethambutol resistance in Mycobacterium tuberculosis isolates from India.
Jadaun GP; Das R; Upadhyay P; Chauhan DS; Sharma VD; Katoch VM
Int J Antimicrob Agents; 2009 May; 33(5):483-6. PubMed ID: 19112008
[TBL] [Abstract][Full Text] [Related]
11. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
[TBL] [Abstract][Full Text] [Related]
12. Role of the dihydrofolate reductase DfrA (Rv2763c) in trimethoprim-sulfamethoxazole (co-trimoxazole) resistance in Mycobacterium tuberculosis.
Köser CU; Summers DK; Archer JA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4951-2; author reply 4952. PubMed ID: 20947864
[No Abstract] [Full Text] [Related]
13. Structural comparison of chromosomal and exogenous dihydrofolate reductase from Staphylococcus aureus in complex with the potent inhibitor trimethoprim.
Heaslet H; Harris M; Fahnoe K; Sarver R; Putz H; Chang J; Subramanyam C; Barreiro G; Miller JR
Proteins; 2009 Aug; 76(3):706-17. PubMed ID: 19280600
[TBL] [Abstract][Full Text] [Related]
14. Multiple mutations modulate the function of dihydrofolate reductase in trimethoprim-resistant Streptococcus pneumoniae.
Maskell JP; Sefton AM; Hall LM
Antimicrob Agents Chemother; 2001 Apr; 45(4):1104-8. PubMed ID: 11257022
[TBL] [Abstract][Full Text] [Related]
15. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
[TBL] [Abstract][Full Text] [Related]
16. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
17. Trade-offs with stability modulate innate and mutationally acquired drug resistance in bacterial dihydrofolate reductase enzymes.
Matange N; Bodkhe S; Patel M; Shah P
Biochem J; 2018 Jun; 475(12):2107-2125. PubMed ID: 29871875
[TBL] [Abstract][Full Text] [Related]
18. Role of mutations in dihydrofolate reductase DfrA (Rv2763c) and thymidylate synthase ThyA (Rv2764c) in Mycobacterium tuberculosis drug resistance.
Köser CU; Veerapen-Pierce RN; Summers DK; Archer JA
Antimicrob Agents Chemother; 2010 Oct; 54(10):4522-3; author reply 5423-5. PubMed ID: 20852189
[No Abstract] [Full Text] [Related]
19. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
[TBL] [Abstract][Full Text] [Related]
20. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
Zheng J; Rubin EJ; Bifani P; Mathys V; Lim V; Au M; Jang J; Nam J; Dick T; Walker JR; Pethe K; Camacho LR
J Biol Chem; 2013 Aug; 288(32):23447-56. PubMed ID: 23779105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
